Fixed-Duration Therapy and MRD-Guided Stopping Across Blood Cancers

“Fixed-duration,” “time-limited” and “treatment-free” appear in titles across CLL, lymphoma, Waldenström, myeloma and CML.

• CLL: Abstract 255 (Oral), “MRD-guided stop-and-restart after fixed-duration ibrutinib-venetoclax… HOVON141/VISION” (Kater; NCT03226301). Abstract 106 (Oral), time-limited pirtobrutinib + venetoclax + obinutuzumab (NCT06967610).
• Follicular lymphoma: Abstract 168 (Oral), fixed-duration subcutaneous mosunetuzumab plus polatuzumab vedotin, 2-year primary analysis of a Phase 2 study (Russler-Germain; NCT05410418).
• Waldenström: Abstract 264 (Oral), fixed-duration zanubrutinib, bendamustine, rituximab, ZEBRA trial (Branagan; NCT06561347).
• Myeloma: Abstract 417 (Oral), abbreviated fixed-duration linvoseltamab consolidation, IMMUNOPLANT (Kazandjian; NCT06376526).
• CML: Abstract 1982 (Poster), predictors of treatment-free remission (Lee).

For trial designers, the common thread is how stopping rules and re-treatment are written into protocols.